Conjunctivitis: Do antibiotics help?

In more than half of all people who have conjunctivitis, the infection goes away without treatment within a week. Antibiotic eye drops or ointment can speed up recovery. Adverse effects are very rare.

Conjunctivitis makes people’s eyes red and inflamed. It often affects both eyes because the infection can easily spread from one eye to the other. Your eyes get watery and produce a yellowish-white discharge that makes your eyelids stick together. They may become very sore too. Conjunctivitis is contagious but often gets better within a week, even without any treatment. So it is often enough to simply wait.

Conjunctivitis is usually caused by bacteria or viruses.  Because conjunctivitis usually goes away so quickly, though, it is generally not worth doing tests to find out if it is a bacterial or viral infection. Doctors often prescribe antibiotics just in case, in the form of eye drops or ointments. Antibiotics only work against bacteria, though, and not against viruses, so they are not always effective.

Some people use non-antibiotic eye drops. The use of cold or warm compresses is common too. But there is not enough research on these approaches to be able to say whether they have a benefit, no effect, or are possibly even harmful. Sometimes conjunctivitis is linked to an allergy. Then it is treated with allergy medicines like antihistamines.

Research on antibiotics in the treatment of conjunctivitis

Two groups of researchers from the Cochrane Collaboration (an international network of researchers) and from various universities in England, the Netherlands and Australia analyzed the results of trials on the treatment of conjunctivitis with antibiotics. They wanted to find out whether antibiotics help in the treatment of ordinary conjunctivitis, as well as which possible disadvantages they have.

The researchers only analyzed the results of studies that compared at least two groups of people. One group of people used antibiotic eye drops or ointments. The other group used non-antibiotic eye drops or ointments, or did not have any treatment at first. The researchers were only interested in studies in which the participants were randomly assigned to one of the treatment groups. This kind of study, called a randomized controlled trial, delivers the most reliable results. Read our information "Evidence-based medicine" to find out more about how good-quality trials are carried out.

The researchers found 12 trials, involving a total of about 4,000 people with conjunctivitis. Both children and adults participated in the trials.

Antibiotics can speed up recovery

Overall, the analysis of the trial results showed that conjunctivitis goes away somewhat faster if antibiotics are used. This is what was found for people who went to see their family doctor because they had conjunctivitis:

• The infection cleared up within one week in 71 out of 100 people who did not use antibiotics.
• The infection cleared up within that same amount of time in 80 out of 100 people who used antibiotics.

In other words, antibiotics were found to speed up recovery in 9 out of 100 people.

In studies that were carried out in a specialist practice, it took a little longer for the infection to clear up – both in the people who used antibiotics and in those who did not use antibiotics. One possible explanation for this is that people who go to see a specialist doctor probably have more severe cases of conjunctivitis. But the antibiotics had a similar beneficial effect to that found in the family doctor trials.

None of the trials reported that antibiotics had adverse effects. The trials did not look into whether antibiotics helped lower the risk of the infection spreading.

Recognizing signs of complications and avoiding the spread of infection

As already mentioned, conjunctivitis usually goes away without treatment. But some symptoms could be signs of more serious problems. These symptoms include worsening vision, increased sensitivity to light, the feeling that you have something in your eye, and a severe headache together with nausea. It is important to see a doctor if you have any of these symptoms.

In people who wear contact lenses, the infection can spread to the cornea (the clear surface of the eye itself). Inflammation of the cornea, also known as keratitis, is not common though: it is estimated that conjunctivitis leads to keratitis in about 3 out of every 10,000 contact lens wearers. In the trials that the researchers included in their analysis, none of the participants developed keratitis.

If conjunctivitis is caused by viruses it can be highly contagious and hard to get rid of. But there are several things that can be done to try to stop viral infections from spreading. Because the virus is easily spread through finger contact, it is important to avoid touching your eyes with your hands, and to wash your hands if you do accidentally touch your eyes. It is also a good idea to have your own towels and washcloths, and not to share them with other people. Another important way to protect others from infection is by not shaking hands with them and not touching their face.

Original Article found at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0005040/

Published by the Institute for Quality and Efficiency in Health Care (IQWiG)Next planned update:
October 2015. You can find out more about how our health information is updated in our text "Informed Health Online: How our information is produced".

References

• IQWiG health information is based on research in the international literature. We identify the most scientifically reliable knowledge currently available, particularly what are known as “systematic reviews”. These summarize and analyze the results of scientific research on the benefits and harms of treatments and other health care interventions. This helps medical professionals and people who are affected by the medical condition to weigh up the pros and cons. You can read more about systematic reviews and why these can provide the most trustworthy evidence about the state of knowledge in our information "Evidence-based medicine". We also have our health information reviewed to ensure medical and scientific accuracy.
• Jefferis J, Perera R, Everitt H, van Weert H, Rietveld R, Glasziou P et al. Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis. Br J Gen Pract 2011; 61(590): e542-548. [Full text]
• Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2012; (9): CD001211. [Summary]

Eye Movements Reveal Reading Impairments in Schizophrenia

A study of eye movements in schizophrenia patients provides new evidence of impaired reading fluency in individuals with the mental illness.

The findings, by researchers at McGill University in Montreal, could open avenues to earlier detection and intervention for people with the illness.

While schizophrenia patients are known to have abnormalities in language and in eye movements, until recently reading ability was believed to be unaffected. That is because most previous studies examined reading in schizophrenia using single-word reading tests, the McGill researchers conclude. Such tests aren't sensitive to problems in reading fluency, which is affected by the context in which words appear and by eye movements that shift attention from one word to the next.

The McGill study, led by Ph.D. candidate Veronica Whitford and psychology professors Debra Titone and Gillian A. O'Driscoll, monitored how people move their eyes as they read simple sentences. The results, which were first published online last year, appear in the February issue of the Journal of Experimental Psychology: General.

eye movement measures provide clear and objective indicators of how hard people are working as they read. For example, when struggling with a difficult sentence, people generally make smaller eye movements, spend more time looking at each word, and spend more time re-reading words. They also have more difficulty attending to upcoming words, so they plan their eye movements less efficiently.

The McGill study, which involved 20 schizophrenia outpatients and 16 non-psychiatric participants, showed that reading patterns in people with schizophrenia differed in several important ways from healthy participants matched for gender, age, and family social status. People with schizophrenia read more slowly, generated smaller eye movements, spent more time processing individual words, and spent more time re-reading. In addition, people with schizophrenia were less efficient at processing upcoming words to facilitate reading.

The researchers evaluated factors that could contribute to the problems in reading fluency among the schizophrenia outpatients -- specifically, their ability to parse words into sound components and their ability to skillfully control eye movements in non-reading contexts. Both factors were found to contribute to the reading deficits.

"Our findings suggest that measures of reading difficulty, combined with other information such as family history, may help detect people in the early stages of schizophrenia -- and thereby enable earlier intervention," Whitford says.

Moreover, fluent reading is a crucial life skill, and in people with schizophrenia, there is a strong relationship between reading skill and the extent to which they can function independently, the researchers note. "Improving reading through intervention in people with schizophrenia may be important to improving their ability to function in society," Titone adds.


Article republished from http://www.sciencedaily.com/releases/2013/02/130219121451.htm

Vitreous Detachment

What is vitreous detachment?

Most of the eye's interior is filled with vitreous, a gel-like substance that helps the eye maintain a round shape. There are millions of fine fibers intertwined within the vitreous that are attached to the surface of the retina, the eye's light-sensitive tissue. As we age, the vitreous slowly shrinks, and these fine fibers pull on the retinal surface. Usually the fibers break, allowing the vitreous to separate and shrink from the retina. This is avitreous detachment.
In most cases, a vitreous detachment, also known as a posterior vitreous detachment, is not sight-threatening and requires no treatment.

Risk Factors

Who is at risk for vitreous detachment?

A vitreous detachment is a common condition that usually affects people over age 50, and is very common after age 80. People who are nearsighted are also at increased risk. Those who have a vitreous detachment in one eye are likely to have one in the other, although it may not happen until years later.

Symptoms and Detection

What are the symptoms of vitreous detachment?

As the vitreous shrinks, it becomes somewhat stringy, and the strands can cast tiny shadows on the retina that you may notice as floaters, which appear as little "cobwebs" or specks that seem to float about in your field of vision. If you try to look at these shadows they appear to quickly dart out of the way.
One symptom of a vitreous detachment is a small but sudden increase in the number of new floaters. This increase in floaters may be accompanied by flashes of light (lightning streaks) in your peripheral, or side, vision. In most cases, either you will not notice a vitreous detachment, or you will find it merely annoying because of the increase in floaters.

How is vitreous detachment detected?

The only way to diagnose the cause of the problem is by a comprehensive dilated eye examination. If the vitreous detachment has led to a macular hole or detached retina, early treatment can help prevent loss of vision.

Treatment

How does vitreous detachment affect vision?

Although a vitreous detachment does not threaten sight, once in a while some of the vitreous fibers pull so hard on the retina that they create amacular hole to or lead to a retinal detachment. Both of these conditions are sight-threatening and should be treated immediately.
If left untreated, a macular hole or detached retina can lead to permanent vision loss in the affected eye. Those who experience a sudden increase in floaters or an increase in flashes of light in peripheral vision should have an eye care professional examine their eyes as soon as possible.
Article republished from http://www.nei.nih.gov/health/vitreous/vitreous.asp#a

What Is Orthokeratology?

What Is Orthokeratology?

In the most basic of terms Accelerated Overnight Orthokeratology or Ortho-k is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye.

Think of the cornea as the eye's equivalent of a watch crystal. It is a clear, dome shaped structure that overlies the colored iris. Its tissue is most similar to clear, wet skin; and like skin it is very pliable. Because the cornea separates the eye from air and the rest of the outside world and because it has a curvature that bends light towards the back of the eye, it is responsible for most of the eye's corrective power and contributes to various conditions such as nearsightedness (myopia), farsightedness (hyperopia), and the blur of astigmatism.

When you choose Ortho-k a few key tests must be performed. Chief among these tests is the determination that your eyes are healthy. The Orthokeratologist will examine the retina and also the health of the outside of the eye. The other key procedure is the mapping of your cornea. To do this an instrument called a Topographer is used. Just like a topographical map of a camping area show hills, plains, and valleys; the topography of the eye shows your doctor exactly how your cornea is shaped. The information from your corneal mapping plus the size of your cornea and the prescription needed to correct your vision are all used to design the retainer lenses (corneal molds) needed to create the Ortho-k effect.

On the day you pick up your Ortho-k retainer lenses you will be instructed in how to insert, remove, and take care your vision retainers. The fit of your retainers will be evaluated and you will be scheduled to be seen after your first night of wear. On day 1, your doctor will re-evaluate your fit and newly corrected vision and another mapping of your cornea will be performed.

Throughout your initial fitting period, your Orthokeratologist will monitor your corneal health and the effectiveness of treatment. At certain times your retainer lens fit may be modified to achieve your goals.

Orthokeratology can produce results in a surprisingly short period of time. The length of treatment to achieve your goals can vary from patient to patient. Factors which can affect the speed of treatment include:

1. your initial prescription
2. corneal rigidity
3. tear quality and quantity
4. your expectations.

We advise patients that they may need to use their retainers every night to maintain their newly corrected vision although some patients are able to vary their wearing time to once every two to four nights. The reason for this is due to the flexibility of your cornea.

Future Treatment for Nearsightedness - Compact Fluorescent Light Bulbs?

ScienceDaily (May 8, 2012) - Researchers at the University of Alabama at Birmingham hope to one day use fluorescent light bulbs to slow nearsightedness, which affects 40 percent of American adults and can cause blindness.

In an early step in that direction, results of a study found that small increases in daily artificial light slowed the development of nearsightedness by 40 percent in tree shrews, which are close relatives of primates.

The team, led by Thomas Norton, Ph.D., professor in the UAB Department of Vision Sciences, presented the study results May 8 at the 2012 Association for Research in Vision and Ophthalmology annual meeting in Ft. Lauderdale.

People can see clearly because the front part of the eye bends light and focuses it on the retina in back. Nearsightedness, also called myopia, occurs when the physical length of the eye is too long, causing light to focus in front of the retina and blurring images.

Myopia has many causes, some related to inheritance and some to the environment. Research in recent years had, for instance, suggested that children who spent more time outdoors, presumably in brighter outdoor light, had less myopia as young adults. That raised the question of whether artificial light, like sunlight, could help reduce myopia development, without the risks of prolonged sun exposure, such as skin cancer and cataracts.

"Our hope is to develop programs that reduce the rate of myopia using energy efficient, fluorescent lights for a few hours each day in homes or classrooms," said John Siegwart, Ph.D., research assistant professor in UAB Vision Sciences and co-author of the study. "Trying to prevent myopia by fixing defective genes through gene therapy or using a drug is a multi-year, multimillion-dollar effort with no guarantee of success. We hope to make a difference just with light bulbs."

Sorting through theories

Work over 25 years had shown that putting a goggle over one eye of a study animal, one that lets in light but blurs images, causes the eye to grow too long, which in turn causes myopia. Other past studies had shown that elevated light levels could reduce myopia under these conditions, whether the light was produced by halogen lamps, metal halide bulbs or daylight. The current study is the first to show that the development of myopia can be slowed by increasing daily fluorescent light levels.

One prevailing theory on myopia-related shape changes in the eye is that they are caused by the blurriness of images experienced while reading or doing other near-work chores. Another holds some people develop myopia because they have low levels of vitamin D, which goes up with exposure to sunlight and could explain the connection between outdoor light and reduced myopia. A third theory, one reinforced by the current results, is that bright light causes an increase in levels of dopamine, a signaling molecule in the retina.

To test the theories, the team used a goggle that lets in light but no images to produce myopia in one eye of each tree shrew. They found that a group exposed to elevated fluorescent light levels for eight hours per day developed 47 percent less myopia than a control group exposed to normal indoor lighting, even though the images were neither more nor less blurry. They also found that animals fed vitamin D supplements developed myopia just like ones without the supplement. Given these results, the team is now experimenting with light levels and treatment times to see if a short, bright light treatment could be effective. They have also begun studies looking at the effect of elevated light on retinal dopamine levels as it relates to the reduction of myopia.

"If we can find the best kind of light, treatment period and light level, we'll have the scientific justification to begin studies raising light levels in schools, for instance," said Norton. "Compact fluorescent bulbs use much less electricity than standard light bulbs, and future programs raising light levels will have more impact the less expensive they are."

Other social bookmarking and sharing tools:

http://www.sciencedaily.com/releases/2012/05/120508163228.htm

Story Source:

The above story is reprinted from materials provided by University of Alabama at Birmingham, via Newswise. The original article was written by Greg Williams.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

New Eye Imaging Techniques Are On the Horizon

ScienceDaily (May 7, 2012) - The same technology used by astronomers to obtain clear views of distant stars is now being used by optometrists to perform incredibly detailed examinations of the living Eye.

An update on new developments in ocular imaging techniques -- and how they may affect clinical vision care in the not-too-distant future -- is presented in an article titled "Adaptive Optics Scanning Laser Ophthalmoscope-based Microperimetry" published in a special May issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

Cutting-edge techniques now allow researchers to visualize the fine structure of the Eye in a way that was "not conceivable 20 years ago," according to a guest editorial by Scott Read OD PhD FAAO (Candidate) and colleagues. "As these advanced imaging methods continue to develop, the potential for imaging ocular structures down to the cellular level in everyday clinical practice has become a reality -- and the potential to improve patient care is truly stunning," Dr Read and coauthors add.

New Techniques Provide Cellular-Level Images of the Living Eye The special issue presents 30 reports on the latest, most advanced techniques for imaging and measurement of various Eye structures: the retina and optic nerve, lens and ciliary body, and the anterior Eye. Written by leading researchers and clinicians, the contributions provide a fascinating look at these remarkable new technologies, with a glimpse of their likely extensions into clinical practice.

As just one example, William S. Tuten, OD, MS, and colleagues of the University of California, Berkeley, report on the development and use of an "adaptive optics scanning laser ophthalmoscope." Adaptive optics refers to the use of advanced techniques to correct for optical aberrations through any transparent media. Originally developed for use in telescopes to correct for the distorting effects of the atmosphere, adaptive optics is now being applied to evaluating the structure and function of the human eye.

Dr. Tuten and colleagues have applied adaptive optics to perimetry -- also known as visual field testing -- on the microscopic scale. Perimetry is an important part of evaluation for patients with vision disorders including macular degeneration, retinitis pigmentosa, and diabetic retinopathy. Perimetry measures vision in all parts of the visual field, including the peripheral vision.

Promising Applications to Improve Clinical Vision Care The new paper describes (and illustrates) the use of adaptive optics-guided microperimtery to assess visual fields at an unprecedented level of detail. The technique can not only show limitations in visual fields, but can trace the defect to individual retinal photoreceptor cells. High-speed tracking is used to correct for normal eye movement, or "jitter," that is practically undetectable using conventional imaging techniques.

In addition, by using microscopic blood vessels as anatomical landmarks, the adaptive optics technique permits repeated studies to be repeated over time at a high level of precision. This offers unique opportunities for studying how treatments work on the cellular level, as well as following the effects of treatment over time in individual patients.

"This technique opens new horizons for clinician-scientists, and later clinicians, to better understand, and plot out, the relationships between vision and the retinal photoreceptors at a microscopic level," comments Anthony Adams, OD, PhD, Editor-in-Chief of Optometry and Vision Science. "It enables a new understanding of vision loss in patients with retinal disorders where there are discrete photoreceptor losses -- for example, macular degeneration."

Adaptive optics-guided microperimetery and other advanced imaging technologies described in the special issue have the potential to revolutionize the management of eye diseases, Dr. Read and colleagues believe. They conclude, "With ongoing improvements in imaging speed and resolution, and with the application of innovative methods to improve the clinical usefulness of ocular imaging techniques, the future of ocular imaging is bright!"

Other social bookmarking and sharing tools:

http://www.sciencedaily.com/releases/2012/05/120507132017.htm

Story Source:

The above story is reprinted from materials provided by Wolters Kluwer Health: Lippincott Williams & Wilkins, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

New Treatment For Age-Related Macular Degeneration Within Sight

With 8 million people at high risk for advanced age-related Macular Degeneration, researchers from Harvard and Japan discovered that the experimental drug, endostatin, may be the cure. A research report describes how giving endostatin to mice significantly reduced or eliminated abnormal blood vessel growth within the eye, which is ultimately why the disease causes blindness.

"Our study provides intriguing findings that may lead to a better treatment of age-related Macular Degeneration," said Alexander Marneros, the first author of the report, "but clinical studies in patients with age-related Macular Degeneration are still necessary."

In this study, researchers describe testing the effects of endostatin on mice lacking this naturally occurring substance. The mice without endostatin were about three times more likely to develop advanced age-related Macular Degeneration (AMD) than normal mice. Then the researchers administered endostatin to both sets of mice. In the mice lacking endostatin, the number of abnormal blood vessels that cause AMD were reduced to normal levels. In control mice with normal levels of endostatin, the number of abnormal blood vessels were practically undetectable.

"With Baby Boomers reaching advanced ages, new treatments are desperately needed to keep age-related Macular Degeneration from becoming a national epidemic," said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. "This research provides hope for those at risk for blindness, and it gives everyone another glimpse of how investments in molecular biology will ultimately pay off in terms of new treatments and cures."

AMD is a progressive disease that affects the part of the eye that allows people to see fine details. The disease gradually destroys sharp, central vision, and in advanced stages ultimately leads to total blindness. Abnormal blood vessel growth, also known as angiogenesis, is a hallmark of advanced AMD. These faulty blood vessels leak fluids and blood, causing catastrophic vision loss.

As the name implies, risk for age-related Macular Degeneration increases with age, and 8 million people are considered to be at high risk for the disease. Of these individuals, approximately 1 to 1.3 million will develop advanced AMD within the next five years. Endostatin is an experimental drug, which is currently being tested to stop cancer in people by restricting the formation of abnormal blood vessels supply blood to tumors. Endostatin is a protein in collagen, and while collagen is used in a range of products for skin care to gelatin desserts, consumption or use of these products does not have any effect on tumors or AMD.

Weissmann added, "This research proves once and for all that endostatin functions as the body's own natural inhibitor of new blood vessel growth as Judah Folkman of Harvard predicted."

This research was published in the December 2007 issue of The FASEB Journal.

http://www.sciencedaily.com/releases/2007/11/071129142449.htm

Story Source:

The above story is reprinted from materials provided by Federation of American Societies for Experimental Biology, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Vitamin D Could Help Combat the Effects of Aging in Eyes

ScienceDaily (Jan. 17, 2012) — Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have found that vitamin D reduces the effects of aging in mouse Eyes and improves the vision of older mice significantly. The researchers hope that this might mean that vitamin D supplements could provide a simple and effective way to combat age-related eye diseases, such as macular degeneration (AMD), in people.

The research was carried out by a team from the Institute of Ophthalmology at University College London and is published in the current issue of the journal Neurobiology of Ageing.

Professor Glen Jeffery, who led the work, explains "In the back of the Eyes of mammals, like mice and humans, is a layer of tissue called the retina. Cells in the retina detect light as it comes into the Eyes and then send messages to the brain, which is how we see. This is a demanding job, and the retina actually requires proportionally more energy than any other tissue in the body, so it has to have a good supply of blood. However, with aging the high energy demand produces debris and there is progressive inflammation even in normal animals. In humans this can result in a decline of up to 30% in the numbers of light receptive cells in the eye by the time we are 70 and so lead to poorer vision."

The researchers found that when old mice were given vitamin D for just six weeks, inflammation was reduced, the debris partially removed, and tests showed that their vision was improved.

The researchers identified two changes taking place in the Eyes of the mice that they think accounted for this improvement. Firstly, the number of potentially damaging cells, called macrophages, were reduced considerably in the Eyes of the mice given vitamin D. Macrophages are an important component of our immune systems where they work to fight off infections. However in combating threats to the aged body they can sometimes bring about damage and inflammation. Giving mice vitamin D not only led to reduced numbers of macrophages in the eye, but also triggered the remaining macrophages to change to a different configuration. Rather than damaging the eye the researchers think that in their new configuration macrophages actively worked to reduce inflammation and clear up debris.

The second change the researchers saw in the eyes of mice given vitamin D was a reduction in deposits of a toxic molecule called amyloid beta that accumulates with age. Inflammation and the accumulation of amyloid beta are known to contribute, in humans, to an increased risk of age-related macular degeneration (AMD), the largest cause of blindness in people over 50 in the developed world. The researchers think that, based on their findings in mice, giving vitamin D supplements to people who are at risk of AMD might be a simple way of helping to prevent the disease.

Professor Jeffery said "When we gave older mice the vitamin D we found that deposits of amyloid beta were reduced in their eyes and the mice showed an associated improvement of vision. People might have heard of amyloid beta as being linked to Alzheimer's disease and new evidence suggests that vitamin D could have a role in reducing its build up in the brain. So, when we saw this effect in the eyes as well, we immediately wondered where else these deposits might be being reduced."

Professor Jeffery and his team then went on to study some of the blood vessels of their mice. They found that the mice that had been given the vitamin D supplement also had significantly less amyloid beta built up in their blood vessels, including in the aorta.

Professor Jeffery continues "Finding that amyloid deposits were reduced in the blood vessels of mice that had been given vitamin D supplements suggests that vitamin D could be useful in helping to prevent a range of age-related health problems, from deteriorating vision to heart disease."

Professor Jeffery thinks that this link between vitamin D and a range of age-related diseases might be linked to our evolutionary history. For much of human history our ancestors lived in Africa, probably without clothes, and so were exposed to strong sunlight all year round. This would have triggered vitamin D production in the skin. Humans have only moved to less sunny parts of the world and adopted clothing relatively recently and so might not be well adapted to reduced exposure to the sun. Secondly, life expectancy in the developed world has increased greatly over the past few centuries, so reduced exposure to vitamin D is now coupled with exceptionally long lifespan.

Professor Jeffery said "Researchers need to run full clinical trials in humans before we can say confidently that older people should start taking vitamin D supplements, but there is growing evidence that many of us in the Western world are deficient in vitamin D and this could be having significant health implications."

Professor Douglas Kell, BBSRC Chief Executive said "Many people are living to an unprecedented old age in the developed world. All too often though, a long life does not mean a healthy one and the lives of many older people are blighted by ill health as parts of their bodies start to malfunction.

"If we are to have any hope of ensuring that more people can enjoy a healthy, productive retirement then we must learn more about the changes that take place as animals age. This research shows how close study of one part of the body can lead scientists to discover new knowledge that is more widely applicable. By studying the fundamental biology of one organ scientists can begin to draw links between a number of diseases in the hope of developing preventive strategies."

http://www.sciencedaily.com/releases/2012/01/120117145234.htm

Story Source:

The above story is reprinted from materials provided by Biotechnology and Biological Sciences Research Council.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Glaucoma as Neurologic Disorder Rather Than Eye Disease?

ScienceDaily (Mar. 7, 2012) - A new paradigm to explain Glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of Glaucoma solely as an eye disease. Instead, they view it as a neurologic disorder that causes nerve cells in the brain to degenerate and die, similar to what occurs in Parkinson disease and in Alzheimer's. The review, led by Jeffrey L Goldberg, M.D., Ph.D., assistant professor of ophthalmology at the Bascom Palmer Eye Institute and Interdisciplinary Stem Cell Institute, describes treatment advances that are either being tested in patients or are scheduled to begin clinical trials soon.

Glaucoma is the most common cause of irreversible blindness worldwide. For many years, the prevailing theory was that vision damage in Glaucoma patients was caused by abnormally high pressure inside the eye, known as intraocular pressure (IOP). As a result, lowering IOP was the only goal of those who developed surgical techniques and medications to treat Glaucoma. Creating tests and instruments to measure and track IOP was crucial to that effort. Today, a patient's IOP is no longer the only measurement an ophthalmologist uses to diagnose Glaucoma, although it is still a key part of deciding how to care for the patient. IOP-lowering medications and surgical techniques continue to be effective ways to protect Glaucoma patients' eyes and vision. Tracking changes in IOP over time informs the doctor whether the treatment plan is working.

But even when surgery or medication successfully lowers IOP, vision loss continues in some Glaucoma patients. Also, some patients find it difficult to use eye drop medications as prescribed by their physicians. These significant shortcomings spurred researchers to look beyond IOP as a cause of Glaucoma and focus of treatment.

The new research paradigm focuses on the damage that occurs in a type of nerve cell called retinal ganglion cells (RGCs), which are vital to the ability to see. These cells connect the eye to the brain through the optic nerve.

RGC-targeted Glaucoma treatments now in clinical trials include: medications injected into the eye that deliver survival and growth factors to RGCs; medications known to be useful for stroke and Alzheimer's, such as cytidine-5-diphosphocholine; and electrical stimulation of RGCs, delivered via tiny electrodes implanted in contact lenses or other external devices. Human trials of stem cell therapies are in the planning stages.

"As researchers turn their attention to the mechanisms that cause retinal ganglion cells to degenerate and die, they are discovering ways to protect, enhance and even regenerate these vital cells," said Dr. Goldberg. "Understanding how to prevent damage and improve healthy function in these neurons may ultimately lead to sight-saving treatments for Glaucoma and other degenerative eye diseases."

If this neurologically-based research succeeds, future Glaucoma treatments may not only prevent Glaucoma from stealing patients' eyesight, but may actually restore vision. Scientists also hope that their in-depth exploration of RGCs will help them determine what factors, such as genetics, make some people more vulnerable to Glaucoma.

http://www.sciencedaily.com/releases/2012/03/120307094659.htm

Story Source:

The above story is reprinted from materials provided by American Academy of Ophthalmology.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

New Glaucoma Test Allows Earlier, More Accurate Detection

Cumbersome Glaucoma tests that require a visit to the ophthalmologist could soon be history thanks to a home test developed by a UA engineer.

Phoenix ophthalmologist Dr. Gholan Peyman demonstrates a prototype Glaucoma test instrument that's noninvasive and simpler to use than current procedures. It can also be used in situations that are difficult or impossible with current tests. (Credit: Image courtesy of University of Arizona College of Engineering)

The self-test instrument has been designed in Eniko Enikov's lab at the UA College of Engineering. Gone are the eye drops and need for a sterilized sensor. In their place is an easy-to-use probe that gently rubs the eyelid and can be used at home.

"You simply close your eye and rub the eyelid like you might casually rub your eye," said Enikov, a professor of aerospace and mechanical engineering. "The instrument detects the stiffness and, therefore, infers the intraocular pressure." Enikov also heads the Advanced Micro and Nanosystems Laboratory.

While the probe is simple to use, the technology behind it is complex, involving a system of micro-force sensors, specially designed microchips, and math-based procedures programmed into its memory.

Enikov began working on the probe four years ago in collaboration with Dr. Gholan Peyman, a Phoenix ophthalmologist. "We went through several years of refinement and modifications to arrive at the current design," Enikov noted.

The National Science Foundation has funded the work, and Enikov and Peyman now are seeking investors to help fund final development and commercialization of the product.

In addition to screening for Glaucoma, an eye disease that can lead to blindness if left untreated, the device corrects some problems with the current procedure, and can be used to measure drainage of intraocular fluid.

"Eye pressure varies over a 24-hour cycle," Enikov said. "So it could be low at the doctor's office and three hours later it might be high. With only a single test, the doctor might miss the problem. Having the ability to take more frequent tests can lead to earlier detection in some cases."

Once the diagnosis is made, several treatments are available. The question then is: How effective are they? Patients could use the probe at home to trace how much the pressure decreases after using eye drop medications, for instance.

"One of the reasons pressure builds up in the eye is because fluid doesn't drain properly," Enikov noted. "Currently, there are no methods available to test drainage."

Current tests require applying pressure directly to the cornea, but only very light pressure is safe to use, and it doesn't cause the fluid to drain.

"Our technique allows us to apply slightly greater pressure, but it's still not uncomfortable," he said. "It's equivalent to rubbing your eye for a brief period to find out if the pressure changes. If it does, we know by how much and if there is a proper outflow of intraocular fluid."

Sometimes, a surgical shunt is used to help fluid drain from the eye. "The problem with Glaucoma shunts is they can plug up over time," Enikov noted. "Or if they're not properly installed, they may drain too quickly. So you would want to know how well the shunt is working and if it is properly installed. Our device could help answer those questions."

In another scenario, certain patients cannot be tested for Glaucoma using currently available procedures. "If a patient had cataract surgery or some other surgery through the cornea, the cornea sometimes thickens," Enikov said. "The cornea's structure is different, but our test remains accurate because it's not applied to the cornea."

Instead, it presses the entire eyeball, much as you might press a balloon to determine its stiffness.

"The innovation with our device is that it's noninvasive, simpler to use and applies to a variety of situations that are either difficult to address or impossible to test using the current procedures," Enikov said. "That's why we're so excited about this probe. It has great potential to improve medical care, and significant commercial possibilities, as well."

http://www.sciencedaily.com/releases/2011/01/110104101331.htm

The above story is reprinted from materials provided by University of Arizona College of Engineering. The original article was written by Ed Stiles.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

The Pupils Are the Windows to the Mind

The eyes are the window into the soul -- or at least the mind, according to a new paper published in Perspectives on Psychological Science, a journal of the Association for Psychological Science. Measuring the diameter of the Pupil, the part of the eye that changes size to let in more light, can show what a person is paying attention to. Pupillometry, as it's called, has been used in social psychology, clinical psychology, humans, animals, children, infants -- and it should be used even more, the authors say.

The Pupil is best known for changing size in reaction to light. In a dark room, your Pupils open wide to let in more light; as soon as you step outside into the sunlight, the Pupils shrink to pinpricks. This keeps the retina at the back of the eye from being overwhelmed by bright light. Something similar happens in response to psychological stimuli, says Bruno Laeng of the University of Oslo, who cowrote the paper with Sylvain Sirois of Université du Québec à Trois-Rivières and Gustaf Gredebäck of Uppsala University in Sweden. When someone sees something they want to pay closer attention to, the Pupil enlarges. It's not clear why this happens, Laeng says. "One idea is that, by essentially enlarging the field of the visual input, it's beneficial to visual exploration," he says.

However it works, psychological scientists can use the fact that people's Pupils widen when they see something they're interested in.

Laeng has used Pupil size to study people who had damage to the hippocampus, which usually causes very severe amnesia. Normally, if you show one of these patients a series of pictures, then take a short break, then show them another series of pictures, they don't know which ones they've seen before and which ones are new. But Laeng measured patients' Pupils while they did this test and found that the patients did actually respond differently to the pictures they had seen before. "In a way, this is good news, because it shows that some of the brains of these patients, unknown to themselves, is actually capable of making the distinction," he says.

Pupil measurement might also be useful for studying babies. Tiny infants can't tell you what they're paying attention to. "Developmental psychologists have used all kinds of methods to get this information without using language," Laeng says. Seeing what babies are interested in can give clues to what they're able to recognize -- different shapes or sounds, for example. A researcher might show a child two images side by side and see which one they look at for longer. Measuring the size of a baby's Pupils could do the same without needing a comparison.

The technology already exists for measuring Pupils -- many modern psychology studies use eye-tracking technology, for example, to see what a subject is looking at, and Laeng and his coauthors hope to convince other psychological scientists to use this method.

http://www.sciencedaily.com/releases/2012/01/120127162800.htm

The above story is reprinted from materials provided by Association for Psychological Science.

Do your eyes hold the secret of life?

In the future, patients in need of perfectly matched neural stem cells may not need to look any further than their own eye.

Researchers reporting in the January issue of Cell Stem Cell, a Cell Press publication, have identified adult stem cells of the central nervous system in a single layer of cells at the back of the eye.

That cell layer, known as the retinal pigment epithelium (RPE), underlies and supports photoreceptors in the light-sensitive retina. Without it, photoreceptors and vision are lost. The new study shows that the RPE also harbors self-renewing stem cells that can wake up to produce actively growing cultures when placed under the right conditions. They can also be coaxed into forming other cell types.

"You can get these cells from a 99-year-old," said Sally Temple of the Neural Stem Cell Institute in Rensselaer, New York. "These cells are laid down in the embryo and can remain dormant for 100 years. Yet you can pull them out and put them in culture and they begin dividing. It is kind of mind boggling."

Temple's group got the RPE-derived stem cells they describe from the eye of donors in the hours immediately after their deaths. But the cells can also be isolated from the fluid that surrounds the retina at the back of the eye, which means they are accessible in living people as well.

"You can literally go in and poke a needle in the eye and get these cells from the subretinal space," she says. "It sounds awful, but retinal surgeons do it every day." By comparison, access to most other neural stem cell populations would require major surgery.

Temple said they were curious about the proliferative potential of the RPE given that the tissue is known to be capable of regenerating entire retinas in salamanders. But that plasticity in adulthood had seemed to be lost in mice and chicks. Still, "given the evolutionary evidence, we thought it was worth revisiting," she said.

They placed RPE tissue taken from 22-year-old to 99-year-old cadavers into many culture conditions to see what they could make the cells do. They found one set of conditions that got the cells dividing. Not all of the RPE cells have this regenerative potential, but perhaps 10 percent of them do.

Further work showed that the cells are multipotent, which means that they can form different cell types, though the researchers admit there is more to do to fully explore the cells' differentiation capacity.

There are other implications as well. For example, these cells may explain diseases in which other tissue types show up in the eye. Their presence also suggests that there might be some way to stimulate controlled repair of the eye in the millions of people who suffer from age-related macular degeneration.

"I think it might be possible," Temple said.

http://www.sciencedaily.com/releases/2012/01/120105131637.htm

The above story is reprinted from materials provided by Cell Press, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Glaucoma, the silent thief...

When it comes to whether or not you will develop exfoliation syndrome (ES) -- an eye condition that is a leading cause of secondary open-angle glaucoma and increased risk of cataract as well as cataract surgery complications -- age, gender and where you live does matter.

"Although many studies from around the world have reported on the burden of the disease, some aspects of the basic descriptive epidemiologic features, which may help shed light on the cause, are inconsistent," said Louis Pasquale, M.D., study co-author and director of Massachusetts eye and Ear's glaucoma Center of Excellence. "In this study we found that women are more vulnerable to this disease then men, that ES is not a disease of Norwegian descent, and that where you live does matter when it comes to developing the disease."

Researchers from the Mass. eye and Ear, Harvard Medical School, Boston, Mass., Department of Medicine, Channing Laboratory, Brigham and Women's Hospital, Boston, Mass., Department of Ophthalmology and Visual Sciences, and University of Michigan, Ann Arbor, Mich., set out to find out how demographic and geographic risk factors are associated with ES. Their study, the "Demographic and Geographic Features of Exfoliation glaucoma in two United States-Based Prospective Cohorts" is published in the January 2012 issue of Ophthalmology.

Researchers used data from 78,955 women in the Nurses' Health Study (NHS) and 41,191 men in the Health Professionals Follow-up Study (HPFS) residing throughout the continental United States who were prospectively followed for 20 years or more and who provided lifetime residence information to examine the descriptive epidemiologic features of ES or exfoliation glaucoma suspect (EGS).

This study confirmed established associations with age and family history and exfoliation glaucoma or exfoliation glaucoma suspect (EG/EGS), as well as provided new data on associations with gender, eye color and ancestry. "Importantly, those with a lifetime residential history of living in the middle tier and south tier of the United States was associated with 47% and 75% reduced risks, respectively, compared with living in the northern tier, and across the life span, residence at age 15 was the most strongly associated with risk, followed by current residence," the authors wrote.

The study showed an increased risk in females, but it was unclear as if gender-specific differences in the eye, such as axial length differences or environmental factors related to lifestyle, account for why women are more at risk for this disease.

Other findings include:

• A positive family history of glaucoma was associated with a more than doubling of risk.


• Neither Scandinavian decent nor Southern European ancestry was associated with risk when compared with the larger reference group of mainly other white persons in the study, which indicates that there may be strong environmental factors that may increase risk among populations in Scandinavian countries. Overall the study lacked adequate power to determine whether incidence rates differed by minority groups.


• Iris ( eye) color did not seem to be a risk factor.

"This large prospective cohort study demonstrates that there is a positive association between latitude and ES risk that is robust and not related to demographic features or other systemic covariates," Dr. Pasquale explained. "Another manuscript we published recently suggests that lower ambient temperature interacts with increased solar exposure to increase the risk of ES. This new work demonstrates a relation between increasing latitude and a condition with a strong predisposition to glaucoma. More work is needed to determine how environmental factors conspire to contribute to ES."

According to the National eye Institute, ES is the major known cause of open-angle glaucoma, and is one of the leading causes of blindness. With the rapid aging of the U.S. population, the number of individuals affected by the disease will increase to more than three million by 2020.

ScienceDaily (Jan. 1, 2012) —

http://www.sciencedaily.com/releases/2012/01/120101143342.htm

The above story is reprinted from materials provided byMassachusetts Eye and Ear Infirmary.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.